Abstract | PURPOSE: EXPERIMENTAL DESIGN: Patients with relapsed/refractory CD20+ B cell non-Hodgkin's lymphoma received i.v. rituximab (375 mg/m2/week for 4 weeks) and PF-3512676 weekly for 4 weeks either i.v. (0.04, 0.16, 0.32, or 0.48 mg/kg) or s.c. (0.01, 0.04, 0.08, or 0.16 mg/kg). An additional extended-treatment cohort received 4 weeks of 0.24 mg/kg s.c. PF-3512676 in combination with rituximab followed by s.c. PF-3512676 alone weekly for 20 weeks. RESULTS: Patients (N = 50) had received a median of three prior therapies (range, 1-11) including rituximab in 80% of patients. Treatment-related adverse events occurred in 11 of 19 (58%) i.v. patients, 15 of 19 (79%) s.c. patients, and all 12 patients in the extended-treatment cohort. Most common adverse events were mild to moderate systemic flu-like symptoms and injection-site reactions (s.c. cohorts only). Grade 3/4 neutropenia occurred in four patients. Objective responses occurred in 12 of 50 (24%) patients overall and in 6 of 12 (50%) patients in the extended-treatment cohort, including 2 patients with rituximab-refractory disease. CONCLUSION:
|
Authors | John P Leonard, Brian K Link, Christos Emmanouilides, Stephanie A Gregory, Daniel Weisdorf, Jeffrey Andrey, John Hainsworth, Joseph A Sparano, Donald E Tsai, Sandra Horning, Arthur M Krieg, George J Weiner |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 13
Issue 20
Pg. 6168-74
(Oct 15 2007)
ISSN: 1078-0432 [Print] United States |
PMID | 17947483
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
- Oligodeoxyribonucleotides
- ProMune
- Toll-Like Receptors
- Rituximab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
(biosynthesis)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Cohort Studies
- Drug Administration Schedule
- Female
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy, pathology)
- Male
- Middle Aged
- Oligodeoxyribonucleotides
(administration & dosage)
- Recurrence
- Rituximab
- Toll-Like Receptors
(agonists)
- Treatment Outcome
|